InMed Gets Conditional Approval for TSX Listing

- March 2nd, 2018

InMed Pharmaceuticals announced it received conditional approval from the TSX to list its common shares in the exchange.

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) announced it received conditional approval from the Toronto Stock Exchange (TSX) to list its common shares in the exchange.

As quoted in the press release:

Final approval of the listing on the TSX remains subject to InMed fulfilling certain customary listing conditions of the TSX on or before the TSX-imposed deadline of May 29, 2018.  The Company expects that it will satisfy such conditions in advance of the TSX-imposed deadline. Upon listing on the TSX, the Common Shares will continue to trade under the symbol ‘IN’.

“Graduating to the TSX is a significant accomplishment for InMed,” said Eric A. Adams, CEO & President.  “This milestone furthers our corporate goal of securing a leadership position in this high-growth sector.  InMed is one of only a few pure-play cannabinoid biopharmaceutical companies to be trading on one of the world’s senior stock exchanges.”

Get the latest Cannabis Investing stock information

Leave a Reply